## Name of the Issue: STAR HEALTH AND ALLIED INSURANCE COMPANY LIMITED

1	Type of Issue	Initial Public	c Offer
2	Issue Size (Rs. Mn) Source: Prospectus	64,0	04.39
3	Grade of issue along with name of the rating agency	/	
	Name Grade	NA NA	
4	Subscription Level (Number of times)		0.95

Source: Basis of allotment

# 5 QIB Holding (as a % of Outstanding Capital) as disclosed to the stock exchanges

Particulars	%
(i) On Allotment *	37.18%
(ii) at the end of the 1st Quarter immediately after the listing of the issue (December 31, 2021)	37.35%
(iii) at the end of 1st FY (March 31, 2022)	37.08%
(iv) at the end of 2nd FY (March 31, 2023)	33.10%
(v) at the end of 3rd FY (March 31, 2024)**	N.A.

\*Shareholding pattern disclosed to Stock Exchanges

\*\* QIB Holding not disclosed as reporting for relevant period has not been completed.

### 6 Financials of the issuer

			(Rs. Million)
Parameters	1st FY (March	2nd FY (March 31,2023)	3rd FY (March
	31, 2022)		31,2024) *
Income from operations	1,02,887	1,17,630.1	Not Available
Net Profit for the period	(10,407)	6,185.9	Not Available
Paid-up equity share capital	5,755	5,816.8	Not Available
Reserves excluding revaluation reserves	57,181	48,522.5	Not Available

\* Financials not available as reporting for the relevant years has not been completed.

### 7 Trading Status

10

The equity shares of the Company are listed on BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE")

The equity shares have not been suspended or delisted.

Status
Frequently Traded
Frequently Traded
Not Available

\* Trading status not disclosed as the relevant fiscal years have not been completed. Source: Stock exchange data.

### 8 Change in Directors of Issuer from the disclosures in the offer document

Particulars	Name of Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2022)	Nil	-
(ii) at the end of 2nd FY (March 31, 2023)	Nil	-
(iii) at the end of 3rd FY (March 31, 2024) $^{\star}$	Not Available	Not Available

\* Changes in Directors of Issuer not updated as the relevant financial years have not been completed

## 9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document	Not applicable
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Notapplicable
Status of utilization of issue proceeds	

(i) As disclosed in the offer document	20,000 million
(ii) Actual utilization	Entirely utilized
(iii) Reasons for deviation, if any	Not applicable

# 11 Comments of monitoring agency, if applicable

(i) Comments on use of funds

(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document

(iii) Any other reservations expressed by the monitoring agency about the end use of funds

Not applicable Not applicable Not applicable

## 12 Pricing Data

Issue Price (Rs.):	900
Designated Stock Exchange:	NSE
Listing Date:	10-Dec-21

Price parameters	At close of listing day (December 10, 2021)	At close of 30th calendar day from listing day (January 10, 2022)	At close of 90th calendar day from listing day	As at the end of 1st FY afte the listing of the issue (March 31, 2022) Closing price (during the FY)		
				0	•	Low (during the FY)
Market Price	906.85	766.95	631.9	710.5	714.9	698.0
NIFTY 50	17,511.3	17,812.7	16,345.35	17,464.8	18,604.5	14,151.4
Sectoral Index	N	lot Applicable			Not Applicable	

Price parameters		As at the end of 2nd FY after the listing of the issue (March 31, 2023)		As at the end of 3rd FY after the listing of the issue (March 31, 2024)		
	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange	518.3	780	469.05	Not Available	Not Available	Not Available
NIFTY 50	17,359.75	18,887.60	15,183.40	Not Available	Not Available	Not Available
Sectoral Index	Not Applicable				Not Applicable	

\* The pricing data is not disclosed as the relevant fiscal years have not been completed

3 Basis for Issue Price					
		As disclosed in offer	At the end of 1st	At the end of	At the end of
Accounting ratio		document, at the end of FY 2021*	FY (March 31, 2022)	1st FY (March 31, 2023)**	1st FY (March 31, 2024)**
	Company				
EPS (Basic & Diluted)	Standalone	-16.54	-18.65	Not Available	Not Available
	Peer Group & Industry Avg	21.18	13.55	Not Available	Not Available
	ICICI Lombard General Insurance Company Ltd.	32.41	25.91	Not Available	Not Available
	New India Assurance Company Limited	9.95	1.18	Not Available	Not Available
	Company				
	Standalone	Not meaningful	Not meaningful	Not Available	Not Available
P/E	Peer Group & Industry Avg^	30.98	72.95	Not Available	Not Available
	ICICI Lombard General Insurance Company Ltd.	46.66	51.27	Not Available	Not Available
	New India Assurance Company Limited	15.30	94.62	Not Available	Not Available
	Company				
	Standalone	-23.69%	-16.54%	Not Available	Not Available
RoNW	Peer Group & Industry Avg	14.31%	7.43%	Not Available	Not Available
	ICICI Lombard General Insurance Company Ltd.	19.81%	13.95%	Not Available	Not Available
	New India Assurance Company Limited	8.81%	0.90%	Not Available	Not Available
	Company				
	Standalone	63.58	109.35	Not Available	Not Available
NAV per share	Peer Group & Industry Avg	137.87	152.78	Not Available	Not Available
	ICICI Lombard General Insurance Company Ltd.	163.56	185.57	Not Available	Not Available
	New India Assurance Company Limited	112.17	119.99	Not Available	Not Available

#### Notes

\* Sourced from Prospectus

\*\*Not available as the relevant fiscal years have not been completed / information not disclosed

^ P/E is calculated as closing market price on NSE as on November 18, 2021/ Basic EPS for the year ended March 31, 2021 sourced from Star health Prospectus

# 14 Any Material Information

Particulars	Date
Listing of equity shares of Shar Health and AlliedInsurance Company Limited	10-dec-21
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011	14-dec-21
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order	21-dec-21
Submission of Report for violation of Code of Conduct under SEBI (Prohibition of Insider Trading) Regulations 2015 ("PIT Regulation")	22-mar-22
Board of Directors of the Company, vide Circular Resolution dated March 4, 2022 had approved the appointment of Mr.V.Jagannathan Whole Time Director & CEO of the Company as the Chairman of the Board with immediate effect ie. March 4, 2022 until the remainder of his tenure i.e, June 16, 2025	4-mar-22
Star Health and Allied Insurance Company Limited has informed the Exchange about demise of Promoter Mr. Rakesh Jhunjhunwala	30-aug-22
Star Health and Allied Insurance Company Limited has informed the Exchange about the Appointment of Mr. Venkataraman S, as Compliance officer of the company w.e.f. 20-Dec-2022 and M/s. Chitra Lalitha & Associates as Secretarial Auditor of the company for the FY 22-23.	09-nov-22
A mail was received on 19.12.2022, alleging access to Company's legacy application (API). Immediately upon receipt of the same, company informed the Regulator, the IRDAI. The matter is currently being reviewed by the Information Security Team of the Company along with External Advisors. Company were advised to lodge a complaint before the Cyber police, which has been already filed.	21-dec-22

Mr. Venkatasamy Jagannathan (DIN: 01196055), Chairman & Chief Executive Officer (CEO) of Star Health and Allied Insurance Company Limited ("the Company") has relinquished his position as CEO and would continue as Non-Executive Director and Non-Executive Chairman of the Board, which will be effective from the close of business hours on May 4,2023. Mr. Shankar Roy Anand shall take over as the Managing Director and Chief Executive Officer of the Company with effect from May 5, 2023	28-Apr-23
Update on Cyber incident – Star Health & Allied Insurance Company Limited - Injunction by Madras High Court - HC has by order dated 7-6-2023 made the orders of the interim injunction granted earlier absolute against the defendants from Dealing with any material accessed by hacking. The HC has also appointed an advocate Commissioner to go to the defendant's place and seize the system used plus downloaded material as claimed and file it with the HC's custody till disposal of the suit or as may be dealt with by the HC	7-jun-23
Resignation of Mr. Venkatasamy Jagannathan as Non-Executive Director of the company w.e.f. Jun 10, 2023.	10-jun-23
during the absence of Ms. Jayashree Sethuraman, Company Secretary & Compliance Officer, who proceeded on Maternity leave, Mr. S. Venkataraman, Vice President & Compliance Officer was nominated to act as Compliance Officer under Companies Act, 2013, SEBI Regulations and other applicable laws. Since Ms. Jayashree Sethuraman, Company Secretary & Compliance Officer, has resumed her duties w.e.f. 19.06.2023, the above arrangement of Mr. S. Venkataraman, Vice President & Compliance Officer is withdrawn. Consequently, Ms. Jayashree Sethuraman shall act as Company Secretary & Company Secretary & Complex Consequently, Ms. Jayashree Sethuraman shall act as Company Secretary & Company Secretary & Complex Consequently, Ms. Jayashree Sethuraman shall act as Company Secretary & Complex Consequently, Ms. Jayashree Sethuraman shall act as Company Secretary & Complex Consequently, Ms. Jayashree Sethuraman shall act as Company Secretary & Complex Consequently, Ms. Jayashree Sethuraman shall act as Company Secretary & Complex Consequently, Ms. Jayashree Sethuraman shall act as Company Secretary & Complex Consequently, Ms. Jayashree Sethuraman shall act as Company Secretary & Complex Consequently, Ms. Jayashree Sethuraman shall act as Company Secretary & Complex Consequently, Ms. Jayashree Sethuraman shall act as Company Secretary & Complex Consequent Sethuraman shall act as Company Secretary & Complex Consequent Sethuraman shall act as Company Secretary & Complex Consequent Sethuraman shall act as Company Secretary & Complex Consequent Sethuraman shall act as Company Secretary & Complex Consequent Sethuraman	19-jun-23
Appointment of Dr S Prakash Strategic Management Executive, consequent to his relinquishment as Managing Director and Director on Board of the Company w.e.f. Jun 26, 2023.	26-jun-23
Appointment Of Mr. Vikas Sharma, Chief Distribution Officer As Key Managerial Personnel	26-jun-23
Appointment Of Mr Amitabh Jain, Chief Operating Officer As Key Managerial Personnel	26-jun-23
Appointment of Mr Himanshu Walia, Chief Marketing Officer as Key Managerial Personnel (KMP) of the company w.e.f. Jun 26, 2023	26-jun-23
Retirement of Dr. P M Nair, Senior Executive Director - Vigilance (KMP)	30-jun-23
In view of the Guidelines on Remuneration to Directors and Key Managerial personnel issued by the Insurance Regulatory and Development Authority of India (IRDAI) dated 30th June 2023 which mandates a maximum age limit of 75 years for Non-Executive Directors, Mr D R Kaarthikeyan (DIN: 00327907) vide email dated July 10, 2023 has tendered his resignation from the Board of the Company with immediate effect i.e. from July 10, 2023.	11-jul-23
Appointment of certain officials of the Company as Key Managerial Personnel (KMP) as mentioned below:	28-jul-23
a) Mr.Chittibabu N as ChiefInnovationOfficer	
b) Mr.Mukesh Sharma as Chief DigitalTransformation Officer	
c) Mr.Biju Menon as Chief Business Officer	
d) Mr.Vishwajeet Mohnot as Chief Compliance Officer (w.e.f. 15 <sup>th</sup> August, 2023)	
The following officials of the Company are re-classified as Non-Key Managerial Personnel (KMP) and Non- Senior Management. Further the said officials shall continue as employees of the Company:	
a) Dr Harikrishnan K as Senior Executive Director, Marketing	
b) Mr. Sundaresan S as Senior Executive Director	
c) Mr. Kumar K C as Senior Executive Director, Human Resources	
d) Mr. Jayaprakash V as Chief Compliance Officer ( w.e.f . 15th August, 2023)	
Company has received a Show Cause Cum Demand Notice from the Directorate General of GST Intelligence, Mumbai Zonal Unit under Section 74(5) of the Central Goods and Services Tax Act, 2017 ("the Act"), October 6, 2023 alleging a tax demand of ₹ 38,99,77,849/-	)9-Oct-23
The alleged demand and the impugned Show Cause Cum Demand Notice pertains to non-payment of GST liability on the premium received by the company as a follower Insurer under a coinsurance arrangement during the period July 2017 to March 2023.	
The Show Cause Cum Demand Notice refers to matters relating to industry wide issues and based on the advice of its tax advisors, the Company will be filing appropriate response to the said Show Cause Cum Demand Notice within the prescribed timelines.	